Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab)
March 25 (Reuters) - Mural Oncology PLC MURA.O:
MURAL ONCOLOGY PROVIDES UPDATE ON PHASE 3 ARTISTRY-7 TRIAL OF NEMVALEUKIN IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER
MURAL ONCOLOGY PLC - TOPLINE RESULTS FOR ARTISTRY-6 TRIAL EXPECTED IN Q2 2025
MURAL ONCOLOGY PLC - NEMVALEUKIN HAS FAVORABLE SAFETY PROFILE IN OVER 800 PATIENTS
MURAL- BASED ON OVERALL SURVIVAL DATA OBSERVED IN INTERIM ANALYSIS IN PLATINUM-RESISTANT OVARIAN CANCER, TO NOT PROGRESS TRIAL TO FINAL ANALYSIS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Musk’s XChat Is Coming to App Store, Meta, Apple and Finance World Are Trembling

What is the CLARITY Act? 2026 Guide to US Crypto Regulation and Stablecoin Yield Rules

Anthropic IPO 2026: What the Claude Mythos Release Delay Means for Investors and Stock Valuation

Microsoft Launches Its Own AI Models and Ditches OpenAI Dependence - Is MSFT Stock a Buy at $370?

Anthropic Claude Mythos Preview Sparks Wall Street Panic: Bessent, Powell Summon CEOs; Cloudflare Tumbles 8%

Tradingkey






